Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Apologies if this has been posted before:
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00053-1/fulltext
Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases
Findings
Findings
PheWAS-MR found that genetically-proxied TYK2 inhibition was associated with lower risk of a wide range of autoimmune diseases. The associations with hypothyroidism and psoriasis were confirmed in MR analysis of tissue-specific TYK2 gene expression and the associations with systemic lupus erythematosus, psoriasis, and rheumatoid arthritis were observed in colocalization analysis.
AF, the cat is out of the bag so to speak. Clearly doesn’t have a clue what he/she/them/ their is talking about. Very amateur disrupter.
Although I have to say sometimes slightly amusing, particularly when it throws its dummy out.
Potnak, I agree we shouldn’t whitewash over MHRA’s request. However I’m inclined to agree that it doesn’t have anything to do with the quality of the submission. The following statement was issued by the MHRA inspectorate, incidentally on the 8th Nov 2022, the same day that SAR released the RNS:
“ Throughout the pandemic we have taken a pragmatic approach to the 'expiry' of GMP Certificates, with these initially extended to the end of 2021 and then to the end of 2022. I can confirm that the 'expiry' of GMP certificates will again be extended until the end of 2023.8 Nov 2022”
I think it’s possible that due to the expiry of certification, MHRA may well have been requesting the review of data as a back stop. Just a thought.
SOG- that’s exactly what it is:
Share dilution is when a company issues additional stock, reducing the ownership proportion of a current shareholder. Shares can be diluted through a conversion by holders of optionable securities, secondary offerings to raise additional capital, or offering new shares in exchange for acquisitions or services.
And yes, it’s happened many times in the past decade.
This article might help some understand why it takes so long to develop potential molecules.
If a company the size of BMS with all its cash and resources takes years to progress candidates, it’s little wonder that a couple of guys in Cambridge might be behind.
https://www.bms.com/life-and-science/science/the-innovation-behind-tyk2-inhibition.html
This Kat can change its spots:
Koolkat01 Dec 2022 09:20
But the same can be said for you Sneck! Why are you and others so, so negative all the time? I'll tell you why..... because you and other negative posters are NOT invested here.
What a clown.
Data from clinical trials conducted in Australia is accepted by key jurisdictions, including the US Food and Drug Administration (FDA) and European Medicines Evaluation Agency (EMEA). This ensures research does not lose momentum. Clinical trials undertaken in Australia do not require US FDA Investigational New Drug (IND) application approval.